NASDAQ:XNCR Xencor Q4 2025 Earnings Results & Report $39.39 +0.80 (+2.07%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$39.40 +0.01 (+0.03%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Xencor beat analyst earnings expectations but missed on revenue in its Q4 2025 results, released February 25, 2026. The company reported EPS of -$0.09 versus the -$0.64 consensus estimate, while revenue of $28.24 million fell short of the $29.97 million estimate by $1.73 million. Revenue decreased 46.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 25, 2026TimeBefore Market OpensConference Call7:00 AM ET Xencor EPS ResultsActual EPS-$0.09Consensus EPS -$0.64Beat/MissBeat by +$0.55One Year Ago EPS-$0.62EPS Beat Rate6 of last 8 quartersXencor Revenue ResultsActual Revenue$28.24 millionExpected Revenue$29.97 millionBeat/MissMissed by -$1.73 millionYoY Revenue Growth-46.60%Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Xencor Q4 2025 Earnings FAQ Did Xencor beat earnings estimates for Q4 2025? Xencor (NASDAQ:XNCR) reported earnings of -$0.09 per share for Q4 2025, beating the consensus estimate of -$0.64. The report was announced on Wednesday, February 25, 2026. What was Xencor's revenue for Q4 2025? Xencor reported revenue of $28.24 million for Q4 2025, against a consensus estimate of $29.97 million. Xencor Earnings HeadlinesXencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657November 9 at 8:01 AM | businesswire.comXencor (NASDAQ:XNCR) Stock Rating Raised to "Buy" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)Show Me The Money: Xencor (XNCR) Delivers Triple-Digit Gains, With XENITH-UC Poised For The Next ActNovember 7, 2026 | rttnews.comXencor (XNCR) Gets a Buy from Canaccord GenuityNovember 6, 2026 | theglobeandmail.comXencor Q3 2026: One-Time Payments Flip the Company to ProfitNovember 5, 2026 | 247wallst.comSee More Xencor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email. Email Address About XencorXencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases. The company’s XmAb technology platform modifies antibody structures to create treatments with properties such as enhanced immune-cell activity or the ability to bind to more than one target. Xencor advances its own drug candidates and works with other biopharmaceutical companies through research collaborations and licensing agreements. Its development programs include antibody-based approaches designed to engage immune cells or block disease-related targets. The company is headquartered in Monrovia, California, and its collaborations extend its work with partners beyond the United States. Founded in 1997, Xencor is led by co-founder and Chief Executive Officer Bassil I. Dahiyat, Ph.D. Its focus is on developing and partnering antibody medicines rather than operating as a broad commercial drug manufacturer.View Xencor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
